Discovery - University of Dundee - Online Publications

Library & Learning Centre

Potential role of non-insulin adjunct therapy in Type 1 diabetes

Potential role of non-insulin adjunct therapy in Type 1 diabetes

Research output: Contribution to journalArticle

View graph of relations

Info

Original languageEnglish
Pages179-188
Number of pages10
JournalDiabetic Medicine
Journal publication date1 Feb 2013
Volume30
Issue2
DOIs
StatePublished
Peer-reviewedYes

Abstract

Despite improvements in the pharmacodynamics of injectable insulin and better insulin delivery systems, glucose control remains suboptimal in the majority of individuals with Type 1 diabetes. Profound defects in the physiological processes that normally maintain glucose homeostasis contribute to the difficulty in achieving glycaemic targets. Non-insulin-based adjunct treatments offer a potential means of complementing intensive insulin therapy in Type 1 diabetes through addressing some of the physiological disturbances that result from endogenous ß-cell destruction, particularly through preservation of ß-cell mass and prevention of apoptosis, and suppression of a-cell glucagon release in the postprandial state. The former approach applies most readily to newly diagnosed C-peptide-positive Type 1 diabetes, while the latter to established C-peptide-negative Type 1 diabetes. This review focuses primarily on the clinical trial data available on the use of non-insulin-based therapies in longer-duration Type 1 diabetes. We conclude that metformin may prove useful in macrovascular disease reduction, while pramlintide, glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors and leptin co-therapies may reduce HbA(1c) , glucose variability, postprandial glucose excursions and body weight. These early studies are encouraging and offer novel and potentially very effective approaches to the treatment of Type 1 diabetes, but the evidence is largely restricted to small, often uncontrolled trials. As such, these therapies cannot be currently recommended for routine clinical practice. There is a clear need to support large, multi-centre randomized controlled trials designed to establish whether adjunct insulin therapy has a place in the modern management of Type 1 diabetes. © 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK.

Documents

Library & Learning Centre

Contact | Accessibility | Policy